← Back to Search

Blood Culture Reduction Approaches for Sepsis (LIBRA Trial)

N/A

Waitlist Available

Led By Charlotte Woods-Hill, MD

Research Sponsored by Children's Hospital of Philadelphia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Non-English speaking

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one year

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to compare two different methods for reducing the overuse of blood cultures in pediatric intensive care units. The study will examine if these strategies have any impact on the rate of blood cultures, patient

Who is the study for?

This trial is for male or female clinicians over 18 years old who work in Pediatric Intensive Care Units (PICUs) and have direct patient care roles. It's not open to those who don't speak English or PICU clinicians reporting directly to the investigator.

What is being tested?

The study compares two strategies: a checklist and targeted messaging, aimed at reducing unnecessary blood culture tests in PICUs. It explores how these strategies affect test rates, patient safety, and evaluates their acceptability and feasibility.

What are the potential side effects?

Since this trial involves non-medical interventions like checklists and messaging rather than drugs or medical procedures, traditional side effects are not applicable. However, there may be indirect impacts on workflow or decision-making processes.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not speak English.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one year

This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Acceptability of Intervention Measure (AIM)

Feasibility of Intervention Measure (FIM)

Intervention Appropriateness Measure

+1 more

Secondary study objectives

Safety Outcomes Post-Intervention

Other study objectives

Qualitative Interview Data

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Loss AversionExperimental Treatment2 Interventions

This intervention consists of targeted messaging and education that the primary study team will create and ask the Arm B sites to deliver to the PICU clinicians, which focuses on the importance of diagnostic stewardship and the current evidence for the benefit/low risk nature of the stewardship program to date. Sites in this arm will also receive a checklist to guide blood culture decisions, that clinicians at sites will be asked to consult and complete prior to ordering or not ordering a blood culture.

Group II: Default BiasExperimental Treatment1 Intervention

This intervention consists of a checklist to guide blood culture decisions, that a clinician in a site randomized to Arm A will be asked to consult and complete prior to ordering or not ordering a blood culture; as the relevant clinical scenario occurs.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Checklist

2013

N/A

~4710

0 / 1Eligibility criteria met